Molecular Partners (MOLN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Molecular Partners and Orano Med have expanded their co-development agreement to create four Radio-DARPin programs, with each company securing commercialization rights to two. The strengthened collaboration aims at advancing targeted cancer therapies, with first-in-human studies expected to begin in 2025. Despite the expansion, Molecular Partners anticipates no immediate financial impact for 2024 and maintains a strong cash position.
For further insights into MOLN stock, check out TipRanks’ Stock Analysis page.